← FDA Drug Approvals (Drugs@FDA)

EPIVIR-HBV

NDA · New Drug Application · Sponsor: GLAXOSMITHKLINE · Approved 1998-12-08

Drug application

FDA Application #

NDA021004

Application type

New Drug Application

Brand name

EPIVIR-HBV

Generic name

Lamivudine

Active ingredients

LAMIVUDINE

Dosage form

SOLUTION

Route

ORAL

Marketing status

Discontinued

Sponsor

GLAXOSMITHKLINE

First approval

1998-12-08

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown